Trials / Completed
CompletedNCT00139737
Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia
Open Extension Study Evaluating the Safety and Tolerability of Oral Ziprasidone in the Treatment of Subjects Who Have Successfully Completed a Previous Ziprasidone Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 344 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
To provide treatment to eligible subjects who have successfully completed one of the following phase III ziprasidone studies, A1281028, A1281044, A1281045 (NCT00136994) or A1281088 (NCT00143351).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ziprasidone | 20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy. |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2005-08-31
- Last updated
- 2021-03-03
- Results posted
- 2010-07-14
Locations
87 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00139737. Inclusion in this directory is not an endorsement.